535 related articles for article (PubMed ID: 15128818)
41. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity.
Shiver JW; Fu TM; Chen L; Casimiro DR; Davies ME; Evans RK; Zhang ZQ; Simon AJ; Trigona WL; Dubey SA; Huang L; Harris VA; Long RS; Liang X; Handt L; Schleif WA; Zhu L; Freed DC; Persaud NV; Guan L; Punt KS; Tang A; Chen M; Wilson KA; Collins KB; Heidecker GJ; Fernandez VR; Perry HC; Joyce JG; Grimm KM; Cook JC; Keller PM; Kresock DS; Mach H; Troutman RD; Isopi LA; Williams DM; Xu Z; Bohannon KE; Volkin DB; Montefiori DC; Miura A; Krivulka GR; Lifton MA; Kuroda MJ; Schmitz JE; Letvin NL; Caulfield MJ; Bett AJ; Youil R; Kaslow DC; Emini EA
Nature; 2002 Jan; 415(6869):331-5. PubMed ID: 11797011
[TBL] [Abstract][Full Text] [Related]
42. Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys.
Liang X; Casimiro DR; Schleif WA; Wang F; Davies ME; Zhang ZQ; Fu TM; Finnefrock AC; Handt L; Citron MP; Heidecker G; Tang A; Chen M; Wilson KA; Gabryelski L; McElhaugh M; Carella A; Moyer C; Huang L; Vitelli S; Patel D; Lin J; Emini EA; Shiver JW
J Virol; 2005 Oct; 79(19):12321-31. PubMed ID: 16160159
[TBL] [Abstract][Full Text] [Related]
43. Both mucosal and systemic routes of immunization with the live, attenuated NYVAC/simian immunodeficiency virus SIV(gpe) recombinant vaccine result in gag-specific CD8(+) T-cell responses in mucosal tissues of macaques.
Stevceva L; Alvarez X; Lackner AA; Tryniszewska E; Kelsall B; Nacsa J; Tartaglia J; Strober W; Franchini G
J Virol; 2002 Nov; 76(22):11659-76. PubMed ID: 12388726
[TBL] [Abstract][Full Text] [Related]
44. Induction of CD8+ T cells to an HIV-1 antigen through a prime boost regimen with heterologous E1-deleted adenoviral vaccine carriers.
Pinto AR; Fitzgerald JC; Giles-Davis W; Gao GP; Wilson JM; Ertl HC
J Immunol; 2003 Dec; 171(12):6774-9. PubMed ID: 14662882
[TBL] [Abstract][Full Text] [Related]
45. A simian replication-defective adenoviral recombinant vaccine to HIV-1 gag.
Fitzgerald JC; Gao GP; Reyes-Sandoval A; Pavlakis GN; Xiang ZQ; Wlazlo AP; Giles-Davis W; Wilson JM; Ertl HC
J Immunol; 2003 Feb; 170(3):1416-22. PubMed ID: 12538702
[TBL] [Abstract][Full Text] [Related]
46. Inhibitory receptor expression on memory CD8 T cells following Ad vector immunization.
Penaloza-MacMaster P; Alayo QA; Ra J; Provine NM; Larocca R; Lee B; Barouch DH
Vaccine; 2016 Sep; 34(41):4955-4963. PubMed ID: 27566899
[TBL] [Abstract][Full Text] [Related]
47. A Recombinant Chimeric Ad5/3 Vector Expressing a Multistage Plasmodium Antigen Induces Protective Immunity in Mice Using Heterologous Prime-Boost Immunization Regimens.
Cabrera-Mora M; Fonseca JA; Singh B; Zhao C; Makarova N; Dmitriev I; Curiel DT; Blackwell J; Moreno A
J Immunol; 2016 Oct; 197(7):2748-61. PubMed ID: 27574299
[TBL] [Abstract][Full Text] [Related]
48. Decreased pre-existing Ad5 capsid and Ad35 neutralizing antibodies increase HIV-1 infection risk in the Step trial independent of vaccination.
Cheng C; Wang L; Gall JG; Nason M; Schwartz RM; McElrath MJ; DeRosa SC; Hural J; Corey L; Buchbinder SP; Nabel GJ
PLoS One; 2012; 7(4):e33969. PubMed ID: 22496775
[TBL] [Abstract][Full Text] [Related]
49. Evaluation of a self-inactivating lentiviral vector expressing simian immunodeficiency virus gag for induction of specific immune responses in vitro and in vivo.
Buffa V; Negri DR; Leone P; Borghi M; Bona R; Michelini Z; Compagnoni D; Sgadari C; Ensoli B; Cara A
Viral Immunol; 2006; 19(4):690-701. PubMed ID: 17201664
[TBL] [Abstract][Full Text] [Related]
50. Induction of protective immunity to anthrax lethal toxin with a nonhuman primate adenovirus-based vaccine in the presence of preexisting anti-human adenovirus immunity.
Hashimoto M; Boyer JL; Hackett NR; Wilson JM; Crystal RG
Infect Immun; 2005 Oct; 73(10):6885-91. PubMed ID: 16177368
[TBL] [Abstract][Full Text] [Related]
51. Circumventing antivector immunity by using adenovirus-infected blood cells for repeated application of adenovirus-vectored vaccines: proof of concept in rhesus macaques.
Sun C; Feng L; Zhang Y; Xiao L; Pan W; Li C; Zhang L; Chen L
J Virol; 2012 Oct; 86(20):11031-42. PubMed ID: 22855499
[TBL] [Abstract][Full Text] [Related]
52. Rhesus immune responses to SIV Gag expressed by recombinant BCG vectors are independent from pre-existing mycobacterial immunity.
Korioth-Schmitz B; Perley CC; Sixsmith JD; Click EM; Lee S; Letvin NL; Frothingham R
Vaccine; 2015 Oct; 33(42):5715-5722. PubMed ID: 26192357
[TBL] [Abstract][Full Text] [Related]
53. Heterologous prime-boost regimens with a recombinant chimpanzee adenoviral vector and adjuvanted F4 protein elicit polyfunctional HIV-1-specific T-Cell responses in macaques.
Lorin C; Vanloubbeeck Y; Baudart S; Ska M; Bayat B; Brauers G; Clarinval G; Donner MN; Marchand M; Koutsoukos M; Mettens P; Cohen J; Voss G
PLoS One; 2015; 10(4):e0122835. PubMed ID: 25856308
[TBL] [Abstract][Full Text] [Related]
54. Adenovirus Serotype 5 Vaccination Results in Suboptimal CD4 T Helper 1 Responses in Mice.
Lee J; Hashimoto M; Im SJ; Araki K; Jin HT; Davis CW; Konieczny BT; Spies GA; McElrath MJ; Ahmed R
J Virol; 2017 Mar; 91(5):. PubMed ID: 28003483
[TBL] [Abstract][Full Text] [Related]
55. A novel adenovirus type 6 (Ad6)-based hepatitis C virus vector that overcomes preexisting anti-ad5 immunity and induces potent and broad cellular immune responses in rhesus macaques.
Capone S; Meola A; Ercole BB; Vitelli A; Pezzanera M; Ruggeri L; Davies ME; Tafi R; Santini C; Luzzago A; Fu TM; Bett A; Colloca S; Cortese R; Nicosia A; Folgori A
J Virol; 2006 Feb; 80(4):1688-99. PubMed ID: 16439526
[TBL] [Abstract][Full Text] [Related]
56. Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre- and postchallenge CD4+ and CD8+ T cell responses.
Hel Z; Nacsa J; Tryniszewska E; Tsai WP; Parks RW; Montefiori DC; Felber BK; Tartaglia J; Pavlakis GN; Franchini G
J Immunol; 2002 Nov; 169(9):4778-87. PubMed ID: 12391187
[TBL] [Abstract][Full Text] [Related]
57. HIV-1 adenoviral vector vaccines expressing multi-trimeric BAFF and 4-1BBL enhance T cell mediated anti-viral immunity.
Kanagavelu S; Termini JM; Gupta S; Raffa FN; Fuller KA; Rivas Y; Philip S; Kornbluth RS; Stone GW
PLoS One; 2014; 9(2):e90100. PubMed ID: 24587225
[TBL] [Abstract][Full Text] [Related]
58. Modification of Ad5 hexon hypervariable regions circumvents pre-existing Ad5 neutralizing antibodies and induces protective immune responses.
Bruder JT; Semenova E; Chen P; Limbach K; Patterson NB; Stefaniak ME; Konovalova S; Thomas C; Hamilton M; King CR; Richie TL; Doolan DL
PLoS One; 2012; 7(4):e33920. PubMed ID: 22496772
[TBL] [Abstract][Full Text] [Related]
59. Fragmentation of SIV-gag vaccine induces broader T cell responses.
Benlahrech A; Meiser A; Herath S; Papagatsias T; Athanasopoulos T; Li F; Self S; Bachy V; Hervouet C; Logan K; Klavinskis L; Dickson G; Patterson S
PLoS One; 2012; 7(10):e48038. PubMed ID: 23118924
[TBL] [Abstract][Full Text] [Related]
60. [Study on Cellular Immune Responses of DNA Vaccine, rAd5 and rMVA Expressing SIV Gag/Env Gene Combined Immunization in Mice].
He X; Chen D; Wang W; Xu K; Zeng Y; Feng X
Bing Du Xue Bao; 2016 Mar; 32(2):170-8. PubMed ID: 27396160
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
